ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers

被引：1
|
作者：
Zammarchi, Francesca
Chivers, Simon
Havenith, Karin
Williams, David G.
Adams, Lauren
Mellinas-Gomez, Maria
Corbett, Simon
Tyrer, Peter
D'Hooge, Francois
Cho, Song
Dimasi, Nazzareno
Hinrichs, Mary Jane
Howard, Phil W.
Hartley, John A.
van Berkel, Patrick H.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3111A
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3111A
引用
收藏
页数：2
相关论文
共 38 条
  • [1] Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
    Cho, Song
    Zammarchi, Francesca
    Williams, David G.
    Havenith, Carin E. G.
    Monks, Noel R.
    Tyrer, Peter
    D'Hooge, Francois
    Fleming, Ryan
    Vashisht, Kapil
    Dimasi, Nazzareno
    Bertelli, Francois
    Corbett, Simon
    Adams, Lauren
    Reinert, Halla W.
    Dissanayake, Sandamali
    Britten, Charles E.
    King, Wanda
    Dacosta, Karma
    Tammali, Ravinder
    Schifferli, Kevin
    Strout, Patrick
    Korade, Martin, III
    Hinrichs, Mary Jane Masson
    Chivers, Simon
    Corey, Eva
    Liu, He
    Kim, Sae
    Bander, Neil H.
    Howard, Philip W.
    Hartley, John A.
    Coats, Steve
    Tice, David A.
    Herbst, Ronald
    van Berkel, Patrick H.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2176 - 2186
  • [2] MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models.
    Cho, Song
    Zammarchi, Francesca
    Monks, Noel R.
    Vashisht, Kapil
    Tammali, Ravinder
    Schifferli, Kevin
    Strout, Patrick
    King, Wanda
    Dacosta, Karma
    Fleming, Ryan
    Williams, David G.
    Havenith, Karin
    Hinrichs, Mary Jane Masson
    Chivers, Simon
    Dimasi, Nazzareno
    Howard, Phil W.
    Hartley, John A.
    Coats, Steve
    Herbst, Ronald
    van Berkel, Patrick H.
    Tice, David A.
    CANCER RESEARCH, 2018, 78 (16) : 25 - 25
  • [3] ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting low HER2-expressing solid cancers
    Zammarchi, F.
    Chivers, S.
    Williams, D. G.
    Adams, L.
    Mellinas-Gomez, M.
    Tyrer, P.
    Corbett, S.
    D'Hooge, F.
    Dissanayake, S.
    Sims, S.
    Havenith, K.
    Howard, P. W.
    Hartley, J. A.
    Van Berkel, P. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S28 - S28
  • [4] ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
    Zammarchi, Francesca
    Havenith, Karin
    Chivers, Simon
    Hogg, Paul W.
    Britten, Charlie
    Dissanayake, Sandamali
    Tyrer, Peter
    Bertelli, Francois
    Hutchinson, Ian
    Masterson, Luke
    Howard, Phil
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
    Zammarchi, Francesca
    Havenith, Karin
    Chivers, Simon
    Hogg, Paul W.
    Britten, Charlie
    Dissanayake, Sandamali
    Tyrer, Peter
    Bertelli, Francois
    Hutchinson, Ian
    Masterson, Luke
    Howard, Phil
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers
    Zammarchi, Francesca
    Havenith, Karin
    de Haan, Lolke
    Kirby, Ian
    Janghra, Narinder
    Gil, Veronica
    Alves, Pedro
    Zaitseva, Kristina
    Kerr, Meghann
    Leatherdale, Ben
    Patel, Afroze
    Thoelke, Marie
    Huang, Shiran
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2023, 83 (07)
  • [7] MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide
    De Bono, Johann S.
    Fleming, Mark T.
    Wang, Judy Sing-Zan
    Cathomas, Richard
    Williams, Marna
    Bothos, John G.
    Balic, Kemal
    Cho, Song Hye
    Martinez, Pablo
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
    Flynn, Michael J.
    Zammarchi, Francesca
    Tyrer, Peter C.
    Akarca, Ayse U.
    Janghra, Narinder
    Britten, Charles E.
    Havenith, Carin E. G.
    Levy, Jean-Noel
    Tiberghien, Arnaud
    Masterson, Luke A.
    Barry, Conor
    D'Hooge, Francois
    Marafioti, Teresa
    Parren, Paul W. H. I.
    Williams, David G.
    Howard, Philip W.
    van Berkel, Patrick H.
    Hartley, John A.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) : 2709 - 2721
  • [9] Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers
    Zammarchi, Francesca
    Havenith, Karin E. G.
    Chivers, Simon
    Hogg, Paul
    Bertelli, Francois
    Tyrer, Peter
    Janghra, Narinder
    Reinert, Halla W.
    Hartley, John A.
    van Berkel, Patrick H.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 582 - 593
  • [10] Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate
    Huang, Yue
    Del Nagro, Christopher J.
    Balic, Kemal
    Mylott, William R., Jr.
    Ismaiel, Omnia A.
    Ma, Eric
    Faria, Morse
    Wheeler, Aaron M.
    Yuan, Moucun
    Waldron, Michael P.
    Peay, Marlking G.
    Cortes, Diego F.
    Roskos, Lorin
    Liang, Meina
    Rosenbaum, Anton I.
    ANALYTICAL CHEMISTRY, 2020, 92 (16) : 11135 - 11144
1234